Drug Trial Radar · NCT07257939
NTI164 in Autism Spectrum Disorder
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Jul 1, 2029
Study completion Jul 1, 2030
Sponsor
- Lead sponsor
- Fenix Innovation GroupIndustry
- Sponsor type
- Industry
- Collaborators
- Neurotech International Limited
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo. Participants will be randomly allocated to either NTI164 or placebo at a 1:1 ratio and blood samples will be collected and surveys completed at baseline and Week 16. This study will expand efficacy and safety data of NTI164 and provide additional mechanism of action data of NTI164 in this patient cohort.
Conditions
- Autism
- Autism Spectrum Disorder
- Autism Disorder
Interventions
NTI164Drug
A CBDA-dominant full-spectrum medicinal cannabis plant extract with extremely low THC.
PlaceboDrug
Placebo oil suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vineland Adaptive Behaviour Scales, 3rd Edition (Vineland-3)Time frame: Baseline, Week 16
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Queensland
Brisbane, Queensland, Australia
Sunshine Coast University Hospital
Sunshine Coast, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.